Harnessing the immune response to target tumors [version 1; referees: 2 approved]

F1000Research

Luisa Manning¹  John Nemunaitis² 

[1] Gradalis, Inc., Dallas, TX, USA;Mary Crowley Cancer Research Center, Dallas, TX, USA;

关键词: Cancer Therapeutics;    Cell Growth & Division;    Cell Signaling;    Genomics;    Immune Response;    Immunomodulation;    Medical Genetics;    Sarcomas;   

DOI  :  10.12688/f1000research.10795.1

来源: DOAJ

【 摘 要 】

Development of “immune-based targeted therapy” in oncology has limited experience with signal pathway modulation. However, as we have become better versed in understanding immune function related to anticancer response, “hints” of specific targets associated with sensitivity and resistance have been identified with targeted immune therapy. This brief review summarizes the relationship of several targeted immune therapeutics and activity associated clinical responsiveness.

【 授权许可】

Unknown